• Origin Energy shareholders reject $10.6 billion offer from Brookfield-led consortium.
  • Uber, Jabil and Builders FirstSource will join the S&P500.
  • UBS will expand its presence in the US market.
  • Amazon orders three SpaceX launches for ultra-high-speed broadband capabilities.
  • Spotify is cutting staff by about 17%.
  • The Blackwells fund wants to acquire a stake in The Wendys.
  • AstraZeneca signed a $247 million agreement with US artificial intelligence company Absci to design an antibody to fight cancer.
  • 888 Holdings rejected a £700 million offer from Playtech in July, according to The Sunday Times.
  • China Evergrande gains more than 20% in trading after a Hong Kong court postpones its decision on the property developer's liquidation yet again.
  • TGS shareholders approve merger with PGS.
  • Orsted launches construction of carbon capture project in Denmark.
  • Suez Canal and Scatec sign $1.1 billion green methanol MOU.
  • Rheinmetall will build its first armored vehicles in Ukraine next year, said its president Armin Papperger in an interview with WiWo magazine.
  • Insurer Aspen chooses New York over London for a $4 billion IPO, according to the FT.
  • Hawaiian Holdings soared by over 180% as Alaska Airlines announced that it was acquiring the group for $1.9 billion.
  • Carmot Therapeutics - Roche is to buy the obesity drug specialist for $2.7 billion, to gain exposure to the growing market for weight-loss drugs.
  • Tesla - Sales of electric vehicles manufactured in China by the carmaker fell by 17.8% year-on-year in November.
  • Boeing - The US Air Force has eliminated the group from the competition to develop the successor to the E-4B Nightwatch, the future nuclear warplane.
  • HF Sinclair - The refiner expects lower capital expenditure for 2024, with maintenance costs expected to fall next year.
  • Virgin Galactic Holdings falls 12.4% as billionaire Richard Branson "ruled out injecting more money into his loss-making space travel company", according to the Financial Times.
  • Eli Lilly said on Friday that the US Food and Drug Administration (FDA) had given a second approval to its drug Jaypirca, which is used to treat a form of blood cancer.